Form 4: Evoke Pharma Director Cashes Out Options Post-Merger

Evoke Pharma director Benjamin C. Smeal cashed out all his stock options following the company's merger with QOL Medical, LLC, effective December 17, 2025.

Summary

• Benjamin C. Smeal, a director of Evoke Pharma Inc., reported changes in beneficial ownership of derivative securities.
• The changes occurred in connection with the Agreement and Plan of Merger, dated November 3, 2025, between Evoke Pharma Inc., QOL Medical, LLC ('Parent'), and QOL-EOS Merger Sub, Inc.
• Effective December 17, 2025 ('Effective Time'), Merger Sub merged with and into Evoke Pharma Inc., with Evoke Pharma continuing as the surviving corporation and a wholly-owned subsidiary of Parent.
• Immediately prior to the Effective Time, all outstanding stock options to purchase Evoke Pharma Common Stock ('Company Option') accelerated, became fully vested, and were automatically canceled and terminated.
• Option holders received a cash amount equal to the product of the aggregate number of shares underlying the Company Option and the difference between $11.00 and the option's per share exercise price.
• Benjamin C. Smeal's stock options, including 5,833 shares with an exercise price of $5.51 and 1,125 shares with an exercise price of $3.453, were converted into cash.
• Following these reported transactions, Benjamin C. Smeal beneficially owns 0 derivative securities.

Sentiment

Score: 6

Explanation: The filing reports the finalization of a merger and the subsequent cash-out of director stock options, which is a neutral event reflecting the completion of a corporate action. It is positive for the option holder receiving cash, but neutral for the company as it ceases independent trading.

Positives

• The merger provided liquidity to stock option holders, including director Benjamin C. Smeal, through a cash payout for their vested options.
• The cash payout for options was calculated based on a per-share value of $11.00, less the exercise price, indicating a premium over the exercise prices of the reported options.

Negatives

• Evoke Pharma Inc. is no longer an independent publicly traded entity, having become a wholly-owned subsidiary of QOL Medical, LLC, which means its stock will no longer trade independently on public exchanges.

Future Outlook

Evoke Pharma Inc. has become a wholly-owned subsidiary of QOL Medical, LLC, indicating its future operations will be integrated under the parent company's strategic direction. No independent forward-looking statements for Evoke Pharma are provided in this filing.

Industry Context

This transaction reflects a consolidation event within the pharmaceutical or biotech industry, where smaller companies like Evoke Pharma are acquired by larger entities like QOL Medical, LLC. Such mergers often aim to combine product portfolios, intellectual property, or market reach, and are a common strategy for growth and market positioning.

Comparison to Industry Standards

• The merger consideration of $11.00 per share for option payouts is specific to this transaction. Without details on Evoke Pharma's prior market valuation, financial performance, or comparable M&A deals in its specific therapeutic area, a direct comparison to industry benchmarks or specific comparable companies is not feasible based solely on this Form 4 filing.
• Valuations in pharmaceutical M&A are typically assessed against recent acquisitions of similar-stage companies, those with comparable drug pipelines, or companies with similar regulatory approvals and market potential.

Stakeholder Impact

• Shareholders: Public shareholders of Evoke Pharma Inc. would have received cash consideration for their shares as part of the merger, as the company is now a wholly-owned subsidiary.
• Option Holders: Individuals like Benjamin C. Smeal, who held stock options, received cash for their vested options, providing liquidity.
• Employees: The filing does not detail the impact on employees, but mergers often lead to organizational restructuring.

Key Dates

Keywords

Evoke Pharma, EVOK, QOL Medical, Merger, Stock Options, Beneficial Ownership, Form 4, Insider Transaction, Corporate Action